Literature DB >> 27830445

Tissue engineering for neurodegenerative diseases using human amniotic membrane and umbilical cord.

Anahí Sanluis-Verdes1, Namibia Sanluis-Verdes1,2, María Jesús Manso-Revilla3, Antonio Manuel Castro-Castro3, Jorge Pombo-Otero4, María Fraga-Mariño5, Jacinto Sanchez-Ibañez1, Nieves Doménech6, María Esther Rendal-Vázquez7.   

Abstract

Regenerative medicine, based on the use of stem cells, scaffolds and growth factors, has the potential to be a good approach for restoring damaged tissues of the central nervous system. This study investigated the use of human amniotic mesenchymal stem cells (hAMSC), human amniotic epithelial stem cells (hAESC), and human Wharton's jelly mesenchymal stem cells (hWJMSC) derived from human umbilical cord as a source of stem cells, and the potential of the human amniotic membrane (HAM) as a scaffold and/or source of growth factors to promote nerve regeneration. The hAMSC and hAESC obtained from HAM and the hWJMSC from umbilical cords were cultured in induction medium to obtain neural-like cells. The morphological differentiation of hAMSC, hAESC and hWJMSC into neural-like cells was evident after 4-5 days, when they acquired an elongated and multipolar shape, and at 21 days, when they expressed neural and glial markers. On other way, the HAM was completely decellularized without affecting the components of the basement membrane or the matrix. Subsequently, hAMSC, hAESC and hWJMSC differentiated into neural-like cells were seeded onto the decellularized HAM, maintaining their morphology. Finally, conditioned media from the HAM allowed proliferation of hAMSC, hAESC and hWJMSC differentiated to neural-like cells. Both HAM and umbilical cord are biomaterials with great potential for use in regenerative medicine for the treatment of neurodegenerative diseases.

Entities:  

Keywords:  Growth factors; Human amniotic membrane; Human umbilical cord; Neural differentiation; Scaffold; Tissue engineering

Mesh:

Year:  2016        PMID: 27830445     DOI: 10.1007/s10561-016-9595-0

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  6 in total

1.  Human amniotic membrane for guided bone regeneration of calvarial defects in mice.

Authors:  Mathilde Fénelon; Olivier Chassande; Jérome Kalisky; Florelle Gindraux; Stéphanie Brun; Reine Bareille; Zoran Ivanovic; Jean-Christophe Fricain; Claudine Boiziau
Journal:  J Mater Sci Mater Med       Date:  2018-06-01       Impact factor: 3.896

2.  Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation.

Authors:  Mohsen Abbasi-Kangevari; Seyyed-Hadi Ghamari; Fahimeh Safaeinejad; Soheyl Bahrami; Hassan Niknejad
Journal:  Front Immunol       Date:  2019-02-20       Impact factor: 7.561

3.  Decellularized Human Chorion Membrane as a Novel Biomaterial for Tissue Regeneration.

Authors:  Laura P Frazão; Joana Vieira de Castro; Cristina Nogueira-Silva; Nuno M Neves
Journal:  Biomolecules       Date:  2020-08-20

4.  miR-146a-3p suppressed the differentiation of hAMSCs into Schwann cells via inhibiting the expression of ERBB2.

Authors:  Wei Chen; Linlin Ji; Zairong Wei; Chenglan Yang; Shusen Chang; Yucheng Zhang; Kaiyu Nie; Lingli Jiang; Yurong Deng
Journal:  Cell Tissue Res       Date:  2021-01-15       Impact factor: 5.249

5.  Regulating Early Biological Events in Human Amniotic Epithelial Stem Cells Using Natural Bioactive Compounds: Extendable Multidirectional Research Avenues.

Authors:  Farhana Ferdousi; Hiroko Isoda
Journal:  Front Cell Dev Biol       Date:  2022-04-01

6.  Microarray analysis of verbenalin-treated human amniotic epithelial cells reveals therapeutic potential for Alzheimer's Disease.

Authors:  Farhana Ferdousi; Shinji Kondo; Kazunori Sasaki; Yoshiaki Uchida; Nobuhiro Ohkohchi; Yun-Wen Zheng; Hiroko Isoda
Journal:  Aging (Albany NY)       Date:  2020-03-29       Impact factor: 5.955

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.